Despite medical advances in the treatment of this type of breast cancer, approximately 22%–25% of HER-2-positive metastatic breast cancer patients have congenital or acquired drug resistance, which is associated with significant morbidity and mortality (Choong et al., 2020). This evidence concerns the gene ERBB2 and breast cancer.